Background: The progressive airway obliteration caused by obliterative bronchiolitis (OB) has been widely noted in the world. In contrast, the obstructive respiratory disorder caused by diffuse panbronchiolitis (DPB) has been reported mainly from Japan. Therefore, there might be a considerable overlap between OB and DPB in Japan. Objectives and Methods: To clarify the clinicopathological similarities as well as the differences between OB and DPB, 15 patients with OB and 6 patients with DPB were evaluated clinicopathologically. Results: The underlying disorders in OB were graft-versus-host disease (GVHD) in 7, rheumatoid arthritis in 3, Kartagener’s syndrome in 2, and polymyositis/dermatomyositis, non-tuberculous mycobacterial disease and mycoplasmal pneumonia in one each. The lung pathology demonstrated that the primary obstructive lesions were in the membranous bronchioli in OB. In contrast, they were confined to the respiratory bronchioli in DPB. In addition, OB was classified into two major morphologic types, namely, constrictive and cellular. Clinical manifestations included cough and/or dyspnea in 13 with OB and in 6 with DPB, chronic parasinusitis in 3 with cellular OB and in 6 with DPB. The pulmonary function tests revealed obstructive impairments in all patients with OB and DPB. The chest CT images showed small centrilobular nodules in 64% of those with OB and in all with DPB. The prognosis of constrictive OB was worse than that of cellular OB and DPB. Conclusions: This study demonstrated that histopathologically marked differences existed between OB and DPB, although striking similarities in clinical manifestations were also noted in both diseases.

1.
King TE Jr: Bronchiolitis; in Schwarz MI, King TE Jr (eds): Interstitial Lung Disease, ed 4. Hamilton, Decker, 2003, pp 787–824.
2.
Geddes DM, Corrin B, Brewerton DA, Davies RJ, Turner-Warwick M: Progressive airway obliteration in adults and its association with rheumatoid disease. Q J Med 1977;184:427–444.
3.
Epler GR: The clinician’s classification of the diseases of the bronchioles; in Epler GR (ed): Diseases of the Bronchioles. New York, Raven, 1994, pp 101–112.
4.
Ryu JH: Bronchiolar disorders. Am J Respir Crit Care Med 2003;168:1277–1292.
5.
Yalcin E, Dogru D, Haliloglu M, Ozcelik U, Kiper N: Postinfectious bronchiolitis obliterans in children: clinical and radiological profile and prognostic factors. Respiration 2003;70:371–375.
6.
Homma H, Yamanaka A, Tanimoto S, Tamura M, Chijimatsu Y, Kira S, Izumi T: Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983;83:63–69.
7.
Maeda M, Saiki S, Yamanaka A: Serial section analysis of the lesions in diffuse panbronchiolitis. Acta Pathol Jpn 1987;37:693–704.
8.
Park MH, Kim YW, Yoon HI, Han SK, Shim YS, Kim WD: Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Am J Respir Crit Care Med 1999;159:526–529.
9.
Nakata K: Diagnostic criteria of diffuse panbronchiolitis. Annual report on the study of diffuse disseminated lung disease. Grant-in-Aid from the Ministry of Health and Welfare in Japan, 1999, pp 109–111 (in Japanese).
10.
Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallry GB Jr, Snell GI, Yousem S: Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297–310.
11.
Homma S, Kawabata M, Kishi K, et al: Diffuse panbronchiolitis in rheumatoid arthritis. Eur Respir J 1998;12:444–452.
12.
Homma S, Kawabata M, Kishi K, Tsuboi E, Narui K, Nakatani T, Uekusa T, Saiki S, Nakata K: Bronchiolitis in Kartagener’s syndrome. Eur Respir J 1999;14:1332–1339.
13.
Colby TV, Myers JL: Clinical and histologic spectrum of bronchiolitis obliterans, including bronchiolitis obliterans organizing pneumonia. Semin Respir Med 1992;13:119–133.
14.
Abernathy EC, Hruban RH, Baumgartner WA, Reitz BA, Huchins GM: The two forms of bronchiolitis obliterans in heart-lung transplant recipients. Hum Pathol 1991;22:1102–1110.
15.
Hebisawa A, Baba M, Yasuda K, Tamura A: Pathology of diffuse bronchiectasis (in Japanese). Pathol Clin Med 2002;20:898–903.
16.
Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A: Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991;58:145–149.
17.
Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M: Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;157:1829–1832.
18.
Kadota J, Sakito O, Kohno S, Sawa H, Mukae H, Oda H, Kawakami K, Fukushima K, Hiratani K, Hara K: A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993;147:153–159.
19.
Umeki S: Anti-inflammatory action of erythromycin: its inhibitory effect on neutrophil NADPH oxidase activity. Chest 1993;104:1191–1193.
20.
Oishi K, Sonoda F, Kobayashi S, Iwagaki A, Nagatake T, Matsushima K, Matsumoto K: Role of interleukin-8 (IL-8) and inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway disease. Infect Immun 1994;62:4145–4152.
21.
Chan A, Allen R: Bronchiolitis obliterans: an update. Curr Opin Pulm Med 2004;10:133–141.
22.
Ross DJ, Lewis MI, Kramer M, Vo A, Kass RM: FK 506 ‘rescue’ immunosuppression for obliterative bronchiolitis after lung transplantation. Chest 1997;112:1175–1179.
23.
Iacono AY, Keenan RJ, Duncan SR, Smaldone GC, Dauber JH, Paradis IL, Ohori P, Grgurich WF, Burckart GJ, Zeevi A, Delgado E, O’Riordan TG, Zendarsky MM, Yousem SA, Griffith BP: Aerosolized cyclosporine in lung recipients with refractory chronic rejection. Am J Respir Crit Care Med 1996;153:1451–1455.
24.
Speich R, Boehler A, Russi EW, Weder W: A case report of a double-blind, randomized trial of inhaled steroids in a patient with lung transplant bronchiolitis obliterans. Respiration 1997;64:375–380.
25.
Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB: Maintenance azithromycin therapy for bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2003;168:121–125.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.